TY - JOUR
T1 - Prognostic factors and survival in low grade gliomas of the spinal cord
T2 - A population-based analysis from 2006 to 2012
AU - Diaz-Aguilar, Daniel
AU - ReFaey, Karim
AU - Clifton, William
AU - Durcanova, Beata
AU - Chen, Selby G.
AU - Deen, H. Gordon
AU - Bydon, Mohamad
AU - Trifiletti, Daniel M.
AU - Pichelmann, Mark A.
AU - Quiñones-Hinojosa, Alfredo
N1 - Publisher Copyright:
© 2018
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: Primary spinal cord tumors are rare, and evidence-based management of these patients remains a source of controversy. This study used a large cohort of low-grade spinal cord astrocytomas to determine the effectiveness of prognostic factors and survival. Methods: The Surveillance, Epidemiology, and End Results (SEER) cancer registry was used to identify patients with WHO grade I-II primary spinal cord astrocytomas from 1973 to 2012; however, patients before 2006 were excluded due to ambiguity diagnosis. Univariate and multivariate Cox proportional hazard models were created to compare survival across covariates and summarized using the Kaplan-Meier method. Results: A total of 561 patients with low-grade glioma (astrocytoma) were identified. Among these, 15.5% of patients received a gross total resection (GTR), 26.1% subtotal resection (STR), and 46.2% unidentified extent of resection. 59.4% did not receive any radiation therapy at any point of the treatment course, while 40.6% underwent radiation therapy. In our cohort, only patients with GTR demonstrated statistically improved survival (HR: 0.22, P < 0.001). Patients with STR had nearly identical survival compared to patients with no surgery (HR: 0.98), and radiotherapy was associated with increased odds of mortality (HR: 1.47, P < 0.001). Multivariate analysis demonstrated a significant survival benefit among patients with younger age, GTR and absence of radiotherapy. Histologic grade did not statistically impact survival. Conclusion: Our study suggests that GTR results in improved survival among patients with low-grade gliomas within the spinal cord. Future, considerable data research efforts will aim to better define the role of radiotherapy and tumor grading in this patient population.
AB - Purpose: Primary spinal cord tumors are rare, and evidence-based management of these patients remains a source of controversy. This study used a large cohort of low-grade spinal cord astrocytomas to determine the effectiveness of prognostic factors and survival. Methods: The Surveillance, Epidemiology, and End Results (SEER) cancer registry was used to identify patients with WHO grade I-II primary spinal cord astrocytomas from 1973 to 2012; however, patients before 2006 were excluded due to ambiguity diagnosis. Univariate and multivariate Cox proportional hazard models were created to compare survival across covariates and summarized using the Kaplan-Meier method. Results: A total of 561 patients with low-grade glioma (astrocytoma) were identified. Among these, 15.5% of patients received a gross total resection (GTR), 26.1% subtotal resection (STR), and 46.2% unidentified extent of resection. 59.4% did not receive any radiation therapy at any point of the treatment course, while 40.6% underwent radiation therapy. In our cohort, only patients with GTR demonstrated statistically improved survival (HR: 0.22, P < 0.001). Patients with STR had nearly identical survival compared to patients with no surgery (HR: 0.98), and radiotherapy was associated with increased odds of mortality (HR: 1.47, P < 0.001). Multivariate analysis demonstrated a significant survival benefit among patients with younger age, GTR and absence of radiotherapy. Histologic grade did not statistically impact survival. Conclusion: Our study suggests that GTR results in improved survival among patients with low-grade gliomas within the spinal cord. Future, considerable data research efforts will aim to better define the role of radiotherapy and tumor grading in this patient population.
KW - Extent of resection
KW - Low grade astrocytoma
KW - National inpatient sample
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=85057811253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057811253&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2018.11.025
DO - 10.1016/j.jocn.2018.11.025
M3 - Article
C2 - 30528541
AN - SCOPUS:85057811253
SN - 0967-5868
VL - 61
SP - 14
EP - 21
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
ER -